EC Number   |
Expression |
Reference |
|---|
   3.5.1.92 | down |
atenolol and diltiazem, two current drugs for treating hypertension, reduce the vanin-1 protein level |
734998 |
| 3.5.1.92 | down |
PPAR-alpha KO mice show a negligible liver vnn1 expression, even after stimulation with various agonists |
757002 |
| 3.5.1.92 | down |
renal vanin-1 protein levels are significantly decreased in rats treated with the higher dose of cisplatin and gentamicin, and vanin-1 immunoreactivity in tubular cells is reduced through cisplatin |
-, 734537 |
| 3.5.1.92 | down |
VNN2 promoter activity and mRNA expression are inhibited by protein kinase A and ERK1/2 inhibitors |
-, 733455 |
| 3.5.1.92 | more |
inactivation of vnn1 on the development of fibrosis, endothelial alterations, and immunological activation in mice with HOCl- and bleomycin-induced systemic sclerosis (SSc) |
-, 757352 |
| 3.5.1.92 | up |
expression of pantetheinase is controlled by the Vnn1 gene and is upregulated in response to free fatty acids, PPAR activation or oxidative stress. PPARalpha-mediated upregulation of Vnn1 translates to enhanced pantetheinase activity in vivo |
-, 756537 |
| 3.5.1.92 | up |
in lipopolysaccharide-treated cells, vanin-1 expression increases 5.1 to 40.2fold. In sodium arsenite-treated cells, vanin-1 expression increases 1.9 to 39.8fold |
719161 |
| 3.5.1.92 | up |
mRNA expressions of vanin-1 significantly increases in the kidney, but not in the colon, during colitis |
-, 734049 |
| 3.5.1.92 | up |
starvation-induced pantetheinase upregulation |
755778 |
| 3.5.1.92 | up |
the messenger RNA expression of VNN1 in A549 cells is significantly increased (by 4.9fold) after influenza A virus (IAV) infection under an elevated concentration of pantetheine. VNN1 mRNA levels are elevated by over 100fold in response to proinflammatory cytokines, especially TNF-alpha and IL-1beta |
755957 |
